Diagnostic and prognostic biomarkers reflective of cardiac remodelling in diabetes mellitus: A scoping review
Authors' conclusion
There is a complex relationship between DM and cardiovascular health, where more research is needed. Current biomarkers reflective of adverse cardiac remodelling in DM are often used to diagnose other CVDs, such as NT-proBNP for heart failure. Hence there is a need for identification of specific biomarkers that can detect early signs of cardiac remodelling in the presence of DM. Further research into these biomarkers and mechanisms can deepen our understanding of their role in DM-associated CVD and lead to better preventative therapies.
Study context
- Population
- Studies of biomarkers of adverse cardiac remodelling in people with diabetes mellitus (DM) and diagnosis and prognosis of subsequent cardiovascular disease (CVD)43 articles
- Outcome
- Biomarkers of cardiac remodelling in CVD and DM
Methodological detailsPRISMA guidelines for Scoping Reviews, studies from 2003 to 2021, MEDLINE, Scopus, Web of Science, PubMed, Cochrane library
- PRISMA guidelines for Scoping Reviews
- Studies from 2003 to 2021
- MEDLINE, Scopus, Web of Science, PubMed, Cochrane library
Main finding
As reported in the abstract
Eligible articles included
43
Different biomarkers identified, each described by ≥2 studies
15
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →